INDIANAPOLIS, INDIANA - MARCH 17: A flag flies above the headquarters campus of Eli Lilly and Company on March 17, 2024 in Indianapolis, Indiana. Lilly, a pharmaceutical company, employs more than 12.000 people in Indianapolis and more than 42,000 worldwide. (Photo by Scott Olson/Getty Images)
Scott Olson/Getty Images
Eli Lilly acquired Kelonia, an in-vivo CAR-T technology company incubated by Venrock, for $3.25 billion in cash upfront and with a total payout of $7 billion if certain milestones are met.
It’s the latest signal of how Eli Lilly, like many of its peers, are using their substantial cash from the GLP-1 boom to diversify beyond the obesity market. It’s also a nice exit for a biotech company whose last round was a Series A in 2022 at a $104 million post-money valuation, per PitchBook data.
“M&A in 2026 feels pretty hot,” said Bryan Roberts, a Venrock partner who led the firm’s investments in Kelonia. “The obesity wave is creating opportunity and cash flow — and fear about what happens post,” he added.
Eli Lilly’s combined revenue from GLP-1s hit $36.5 billion in 2025 — more than half of the pharmaceutical giant’s total revenue of $65.18 billion for the year. For Novo Nordisk, Eli Lilly’s main competitor in the category, GLP-1 products including Ozempic and Wegovy comprised approximately 75% of its total revenue.
But the huge profits on GLP-1s may start to taper off as more options become available, prices drop, and some users drop off the medication. Compared to even six months ago, there are more GLP-1 options on the market and companies are very quickly developing novel therapies, including in oral GLP-1s as alternatives to injectables.
And with patent cliffs looming for several of the biggest money-maker drugs that aren’t GLP-1s, buyers are getting more aggressive in an effort to protect their top-line revenue growth.
Even if companies like Eli Lilly are still generating billions from the weight-loss drug category, slowing growth could have negative effects on stock price, especially when combined with patent cliff deadlines. “If you’ve just started making an extra $10 or $20 billion in revenue, when that specific product goes away, you don’t want a drop in revenue,” said Roberts.
Meanwhile, biotech has been getting a boost lately. There have already been more than 20 M&A deals at over $1 billion in biotech since the start of this year, and the IPO window has been slowly creaking open. On the private side, valuations for venture growth deals have skyrocketed, per PitchBook’s Q4 2025 Biopharma VC Trends report.
“It certainly gives acquisition targets leverage, but it’s hard to call [the Kelonia deal] an overpay right now,” said Ben Zercher, senior biotech analyst at PitchBook. “This technology should (in theory) have more durable expression than some other approaches, so there’s a premium there.”
Recent News
Q&A: Bullhound’s Alon Kuperman on Revolut’s path to $1T
Former Carlyle Asia and Warburg Pincus execs launch pan-Asian secondaries fund
Learn about our editorial standards.